BPC-157 + TB-4 FRAG - 20+20mg

SPECIFICATIONS

Product Code: BPTBF20

BPC-157 - 20mg

Sequence: Gly-Glu-Pro-Pro-Pro-Gly- Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val

Molecular Formula: C62H98N16O22

Molecular Weight: 1419.556 g/mol

CAS: 137525-51-0

Purity: Technical / Research Grade ≥99%

THYMOSIN BETA-4 Frag - 20mg

Sequence: Ac-Leu-Lys-Lys-Thr-Glu-Thr-Gln

Molecular Formula: C38H68N10O14

Molecular Weight: 889.018 g/mol

CAS number: 885340-08-9

Purity: Technical / Research Grade ≥98%

General Properties (Common)

Other details: No TFA Salt

Form: Lyophilized powder

Color: White

Storage temperature: -20°C

Source: Synthetic

Safety classification: Standard handling

DESCRIPTION

BPC-157

BPC-157 is a synthetic peptide derived from a sequence naturally present in gastric juice, where endogenous BPC peptides are involved in maintaining gastrointestinal mucosal integrity. In preclinical research models, BPC-157 has been used to investigate mechanisms related to epithelial barrier stability, extracellular matrix organization, and tissue repair signaling under experimental conditions.

Fibroblast activity and extracellular matrix research (preclinical)

In cell culture systems and animal models, BPC-157 has been studied for its influence on fibroblast proliferation and migration, two key cellular processes involved in wound healing and connective tissue remodeling. Fibroblasts are responsible for the deposition of extracellular matrix components such as collagen, fibrin, and elastin, and experimental modulation of their activity is commonly used to study tissue regeneration mechanisms.

Angiogenesis and ischemia-related models (preclinical)

BPC-157 has been investigated in preclinical angiogenesis assays to explore its effects on endothelial cell behavior and collateral vessel formation. In animal models of ischemic injury, experimental exposure to BPC-157 has been associated with altered vascular responses, which are used to study blood supply restoration and tissue recovery dynamics in gastrointestinal, cardiovascular, neural, and musculoskeletal research contexts.

Musculoskeletal and connective tissue research (preclinical)

In in vitro and in vivo models of tendon, ligament, and bone injury, BPC-157 has been examined for its role in cell recruitment, vascular density, and connective tissue organization. These experimental systems are used to explore why tissues with limited blood supply exhibit delayed repair and how angiogenesis and fibroblast migration contribute to structural recovery under laboratory conditions.

Oxidative stress and inflammatory signaling models (preclinical)

In rodent models, BPC-157 has been studied for its interaction with oxidative stress markers, including pathways involving nitric oxide signaling and lipid peroxidation indices. These studies investigate antioxidant-related mechanisms and their contribution to tissue protection in experimental gastrointestinal and systemic inflammation models.

Drug interaction and tissue stress research (preclinical)

BPC-157 has also been explored in preclinical models assessing tissue responses to pharmacologically induced stress, including systems designed to study adverse tissue effects associated with various compound classes. These investigations focus on cellular resilience, barrier protection, and repair signaling, rather than mitigation of drug effects in clinical settings.

Neurobiology and brain–gut axis research (preclinical)

Experimental studies have examined BPC-157 in preclinical neurobiological models to explore interactions between peripheral tissues and central signaling pathways, including serotonergic and dopaminergic systems. These models are used to study brain–gut communication and stress-related signaling, without implying behavioral or therapeutic outcomes.

THYMOSIN BETA-4 FRAG

Thymosin Beta-4 Fragment, also referred to as TB-500 in research contexts, is a peptide widely used in preclinical research models to study cell migration, cytoskeletal dynamics, and tissue repair mechanisms.

Actin Regulation and Cell Migration

Tβ4 interacts with G-actin, influencing cytoskeletal organization and cell motility in keratinocytes, endothelial cells, and fibroblasts.

Angiogenesis and Tissue Repair Models

Tβ4 has been extensively studied in angiogenesis assays and wound-healing models involving cutaneous, corneal, muscular, and cardiac experimental systems.

Inflammatory Signaling Research

In animal models, Tβ4 has been investigated for modulation of cytokine-associated signaling pathways, including NF-κB activity and matrix metalloproteinase expression.

Cardiovascular and Neurological Research Models

Tβ4 has been included in preclinical myocardial injury and neurological models to explore cell survival, migration, and tissue remodeling pathways.

REFERENCES

All information presented above is derived from in vitro experiments, animal studies, and other preclinical research models. These data are intended solely for basic scientific investigation of biological mechanisms and do not imply any therapeutic, diagnostic, preventive, or clinical use in humans or animals. 

N. Shomali et al., "A new insight into thymosin β4, a promising therapeutic approach for neurodegenerative disorders" [PubMed]

S. Munshaw et al., "Thymosin β4 protects against aortic aneurysm via endocytic regulation of growth factor signaling" [PubMed]

G. Renga et al., "Thymosin β4 limits inflammation through autophagy" [PubMed]

Y. Wang et al., "Adjunctive Thymosin Beta-4 Treatment Influences MΦ Effector Cell Function to Improve Disease Outcome in Pseudomonas aeruginosa-Induced Keratitis" [PubMed]

K.W. Freeman et al., "Regenerative protein thymosin beta-4 is a novel regulator of purinergic signaling" [PubMed]

G. Sosne et al., "Thymosin beta 4 promotes corneal wound healing and decreases inflammation in vivo following alkali injury" [PubMed]

J. Zhang et al., "Thymosin beta4 promotes oligodendrogenesis in the demyelinating central nervous system" [PubMed]

Rui Yu et al., "Recombinant Human Thymosin Beta-4 Protects against Mouse Coronavirus Infection" [PubMed]

M. Hsieh et al., "Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation" [PubMed]

J. Vukojevic et al.,  "Rat inferior caval vein (ICV) ligature and particular new insights with the stable gastric pentadecapeptide BPC 157" [PubMed]

N. Jelovac et al., "Pentadecapeptide BPC 157 attenuates disturbances induced by neuroleptics: the effect on catalepsy and gastric ulcers in mice and rats" [PubMed]

D. Strinic et al., "BPC 157 counteracts QTc prolongation induced by haloperidol, fluphenazine, clozapine, olanzapine, quetiapine, sulpiride, and metoclopramide in rats" [PubMed]

K. Skrlec et al., "Engineering recombinant Lactococcus lactis as a delivery vehicle for BPC-157 peptide with antioxidant activities" [PubMed]

C. Chang et al., "The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration" [PubMed]

S. Seiwerth et al., "BPC 157 and Standard Angiogenic Growth Factors. Gastrointestinal Tract Healing, Lessons from Tendon, Ligament, Muscle and Bone Healing" [PubMed]

P. Sikiric et al., "Novel Cytoprotective Mediator, Stable Gastric Pentadecapeptide BPC 157. Vascular Recruitment and Gastrointestinal Tract Healing" [PubMed]

DISCLAIMER

This product is intendend for lab research and development use only. These studies are performed outside of the body. This product is not medicines or drugs and has not been approved by the FDA or EMA to prevent, treat or cure any medical condition, ailment or disease. Bodily introduction of any kind into humans or animals is strictly forbidden by law. This product should only be handled by licensed, qualified professionals.

All product information provided on this website is for informational and educational purposes only.